Novartis, Australia & New Zealand

What Novartis, Australia & New Zealand does

Novartis Pharmaceuticals Australia Pty Ltd is the Australian and New Zealand operating subsidiary of Novartis AG (NYSE: NVS), the global Swiss pharmaceutical company formed in 1996 through the merger of Ciba-Geigy and Sandoz. The entity operates as an innovative medicines business organised around four core therapeutic areas — cardiovascular/renal/metabolic, immunology, neuroscience, and oncology — distributing a portfolio that includes Zolgensma (Australia's first PBS-listed gene therapy for spinal muscular atrophy), Gilenya (first TGA-approved oral treatment for paediatric multiple sclerosis), and Mayzent. It is headquartered at a purpose-built campus at Macquarie Park, Sydney, with additional offices in Melbourne, Brisbane, Perth, and Auckland, supported by an enterprise field sales and medical science liaison model targeting healthcare professionals, hospitals, and healthcare systems.

The company generates revenue through the sale of prescription pharmaceutical products across its four therapeutic areas, distributed via community pharmacies, hospitals, and direct healthcare professional prescription channels. In Australia, medicines are primarily reimbursed through the Pharmaceutical Benefits Scheme (PBS); in New Zealand, through Pharmac. Specialty products such as Zolgensma are also made available through the global Managed Access Program (gMAP) for qualifying patients. Novartis ANZ does not disclose pricing publicly as medicines are prescription-only and subject to government reimbursement schemes. Marketing reach is delivered through MedHub AU for healthcare professionals, clinical-trial recruitment via recruiting-trials.novartis.com, the Novartis Connect patient platform, patient-education resources, medical congress participation, and partnerships with patient groups.

Strategic activity in 2022-2023 includes new product launches (Zolgensma, Gilenya paediatric MS), the opening of the Macquarie Park campus, and partnerships with Biocurate (early-stage drug discovery), Telstra Health and Monash University (cardiovascular disease screening), and the Australian government (COVID-19 hydroxychloroquine supply via Novartis Assist). The subsidiary holds no independent funding or external investors, operating wholly under the strategic and financial control of Novartis AG.

Name

Novartis, Australia & New Zealand

Legal name

Novartis Pharmaceuticals Australia Pty Ltd

Website

https://novartis.com.au

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Novartis Australia & New Zealand is the ANZ subsidiary of Novartis AG, selling innovative prescription medicines across cardiovascular, immunology, neuroscience, and oncology through PBS and Pharmac reimbursement channels to healthcare professionals and patients in Australia and New Zealand.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Medical Oncology (HLAKAFAB)

Keywords

• Innovative medicines
• Pharmaceutical products
• Gene therapy
• Oncology treatments
• Clinical research

Headquarters

HQ city

North Sydney

HQ country

Australia

HQ region

Oceania

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Prescription Pharmaceutical Products: Novartis generates revenue through the sale of prescription medicines across therapeutic areas including cardiovascular, immunology, neuroscience, and oncology. Products are distributed via pharmacies and hospitals, with significant portion reimbursed through Australia's PBS and New Zealand's pharmac system.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Novartis Australia & New Zealand develops, manufactures, and distributes prescription pharmaceutical medicines across four core therapeutic areas: cardiovascular/renal/metabolic, immunology, neuroscience, and oncology. The company markets breakthrough therapies including Zolgensma (gene therapy for spinal muscular atrophy), Gilenya and Mayzent (multiple sclerosis treatments), and an oncology portfolio featuring radioligand therapies. Products are distributed through Australia's Pharmaceutical Benefits Scheme (PBS), New Zealand's Pharmac system, hospitals, and community pharmacies.

Product overview

Novartis Australia & New Zealand operates as an innovative medicines company organized around four core therapeutic areas: Cardiovascular, Renal and Metabolic; Immunology; Neuroscience; and Oncology. The company distributes its pharmaceutical portfolio through separate channels for consumers and healthcare professionals, offering medicines such as Zolgensma (gene therapy for spinal muscular atrophy), Gilenya (oral MS treatment), and Mayzent. Additional offerings include the Novartis Connect patient platform and access to clinical trials through the Novartis Pipeline and recruiting trials portal. The organization focuses on discovering and developing breakthrough treatments and delivering them to patients across Australia and New Zealand.

Differentiator

Problem solved

Functional benefit

Products and services

• Zolgensma (onasemnogene abeparvovec) Gene therapy treatment for spinal muscular atrophy (SMA), Australia's first gene therapy to be made available on the Pharmaceutical Benefits Scheme. It is administered to patients with SMA as a one-time treatment.
• Gilenya (fingolimod) Fingolimod capsule medication for multiple sclerosis treatment, TGA-approved as the first licensed oral treatment for paediatric MS in Australia.
• Mayzent (siponimod) Siponimod medication for neuroscience therapeutic area, referenced in risk minimisation materials for healthcare professionals and patients with neurological conditions.
• Cardiovascular, Renal and Metabolic Medicines Portfolio Innovative medicines addressing cardiovascular diseases, renal conditions, and metabolic disorders, sold through prescription channels.
• Immunology Medicines Portfolio Innovative medicines for immunological conditions and inflammatory diseases, sold through prescription channels.
• Neuroscience Medicines Portfolio Innovative medicines addressing neurological and neurodegenerative conditions including multiple sclerosis, sold through prescription channels.
• Oncology Medicines Portfolio Innovative cancer treatments and oncology therapies including radioligand therapies, sold through prescription channels.

Quantifiable outcome

• Australia's first gene therapy babies born with SMA treated with Zolgensma now available on PBS
• +1 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Telstra Health and Monash UniversitycoreStrategic or Co-development Partner · 27 March 2023Novartis joined forces with Telstra Health and Monash University to tackle Australia's number one killer - heart disease. This multi-partner initiative focuses on screening pilots and awareness programs for cardiovascular health, combining technology, academic research, and pharmaceutical expertise.
• Australian Healthcare SystemcoreStrategic or Co-development Partner · 16 December 2022Partnership with Australian government for supply of hydroxychloroquine during initial COVID-19 response. Novartis Assist program supported Australian government's initial supply needs.
• Biocurate Pty LtdcoreStrategic or Co-development Partner · 13 December 2022Novartis Australia announced collaboration with Biocurate to accelerate early-stage drug discovery. This partnership represents a strategic effort to advance preclinical development and leverage local biotech expertise in the Australian research ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MSD (Merck Sharp & Dohme) Australia: Subsidiary of Merck & Co. with established Australian operations across oncology, vaccines, and general medicine. Competes for the same PBS listings, healthcare-professional audiences, and specialty indications as Novartis ANZ.
• Johnson & Johnson Innovative Medicine (Janssen) Australia: Janssen's Australian operations cover immunology, oncology, neuroscience, and pulmonary hypertension, mirroring Novartis ANZ's therapeutic-area footprint and PBS/Pharmac commercialization model.
• Bristol Myers Squibb Australia: BMS Australia focuses on oncology, hematology, and immunology — directly overlapping with Novartis ANZ's oncology and specialty-care portfolio and sharing the same hospital-channel commercial approach.
• AbbVie Australia: AbbVie's ANZ operations in immunology, oncology, and neuroscience. Particularly relevant overlap with Novartis ANZ's immunology franchise and specialty-care delivery model.
• Roche Products Australia: Subsidiary of F. Hoffmann-La Roche, with deep ANZ footprint across oncology, immunology, and neuroscience. Direct competitor on hospital-administered biologics and innovative therapies with similar PBS/Pharmac access pathways.
• GSK Australia: GlaxoSmithKline's Australian subsidiary operating in specialty medicines, vaccines, and immunology. Comparable ANZ footprint and reimbursement-driven commercial model.
• Sanofi Australia & New Zealand: Sanofi's ANZ subsidiary covering immunology, vaccines, and specialty care. Direct competitor in immunology and cardiovascular franchises, with similar enterprise field-sales and PBS/Pharmac distribution.
• Pfizer Australia: Australian subsidiary of Pfizer Inc., one of the largest innovative medicines companies in ANZ. Operates across similar therapeutic areas (cardiovascular, oncology, immunology, neuroscience) and distributes via PBS and Pharmac using an analogous enterprise field-sales model.
• Eli Lilly Australia: Australian operations of Eli Lilly covering oncology, diabetes, immunology, and neuroscience. Direct competitor on PBS-listed specialty products with overlapping prescriber base.
• AstraZeneca Australia: Australian arm of AstraZeneca, focused on oncology, cardiovascular/renal/metabolic, and respiratory. Competes with Novartis ANZ's oncology and cardiometabolic portfolios via parallel PBS pathways and similar field-sales coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/novartis-australia

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis, Australia & New Zealand